Emerging therapeutic application of clemastine: a review of recent patents updates

Abstract

Clemastine, a first-generation antihistamine traditionally used for treating allergic rhinitis and urticaria, has recently gathered interest due to its potential therapeutic applications beyond its antihistaminergic properties. This review examines recent patent filings (2015-2024) to elucidate the emerging therapeutic landscape for this compound. The analysis reveals various potential applications, including neurodegenerative disorders, cardiovascular diseases, and cancer treatment. Specifically, several studies focus on its ability to promote remyelination in multiple sclerosis and other demyelinating disorders, highlighting its potential neuroprotective effects. Recent findings suggest its efficacy in treating heart failure and arrhythmias, possibly through its action on cardiac ion channels. In oncology, patents propose this compound as an adjuvant therapy to enhance the efficacy of existing treatments and potentially overcome drug resistance. This review also explores combination therapies involving this drug, which aim to synergize its effects with other active compounds. The patent literature indicates a significant change in the therapeutic potential of ethanolamine derivatives, from a simple antihistamine to a multifaceted drug candidate with far-reaching implications across various medical fields. These developments emphasize the importance of repurposing existing drugs and highlight Clemastine as a promising candidate for further clinical investigation in multiple therapeutic areas.

Keywords: Alzheimer’s disease; Hypoxic-ischemia; Multiple sclerosis; Patents; Spinal cord injury.